Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04657445
Other study ID # 931/17-11-2020
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 17, 2020
Est. completion date June 30, 2021

Study information

Verified date September 2022
Source University Hospital, Ioannina
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an observational data and recording study. The aim of our study is to investigate the effect of SARS-COV2 infection on patients' sense of smell and taste, through quality control measurements using optic analogue scale (VAS) in hospitalized and in home-quarantined patients.


Description:

Eligible participants who will be recruited in this research protocol will be adult patients who are diagnosed positive for SARS-COV2, infection with Real Time Polymerase Chain Reaction Test (RT-PCR). The study population will be divided in two groups. The first group will be consisted with positive patients that were referred to either the Emergency Department (ED) of Infectious Diseases or at the Outpatient Clinic screening for SARS-COV2 and are being self-quarantined at home. The participants will be hospitalized patients in the Infectious Diseases Unit (IDU) of the University General Hospital of Ioannina. The examination will be performed at the moment of diagnosis both for self-quarantine patients and for in hospitalized patients. The follow up evaluation will be a re-examination, performed at least four weeks after the moment of diagnosis. The time internal of reassessing the patients chosen according to current literature, estimated that is the minimum reassessment interval and seems to be a reference time for either progression stabilization or recession of the symptoms of anosmia/ ageusia (12, 13). Patients will be asked to evaluate their olfactory and gustatory abilities through the visual analogue scale (VAS), at three time points: 1.before infection( as they can recall it), 2. at the time of diagnosis and 3. four weeks later(14). Patients' scoring will be recorded in a horizontal presentation of 100 VAS points, where zero refers to no smell or taste while 100 refers to normal sensation. In addition, patients will rate their nasal obstruction and rhinorrhea on a similar VAS scale, where 0 refers to a completely blocked nose and an excessively runny nose while 100 indicates normal nasal breathing and a no runny nose. All patients will assess the intensity of the olfactory and taste function, through a self testing them at home. Patients will rate from 0 to 100 the intensity of smell, after being exposed to five common household odors (ie lemon juice, oregano, instant coffee, toothpaste and mint gum).The choice of these substances is based on their influence at the irritation of the trigeminal nerve. The intensity of taste function will be evaluated using four(4) substances: sugar, salt, lemon juice and instant coffee (decaffeinated), that represent the following 4 basic quality flavors:sweet, salty, sour and bitter. Every patient will have to receive orally half a teaspoon of each testant and report the quality of taste perception. After each testant they have to rinse their mouth with tap water. Bitter testant will have to be tested in the end. Patient demographics, associated symptoms, and comorbidities will be recorded. The patients will have to report and fill in symptoms such as fever, cough, shortness of breath or dyspnea, fatigue, muscle aches, runny nose, blocked nose, loss of smell, and loss of taste. The results will be recorded in a questionnaire. Covid-19 positive patients recovering at home, will be informed for the study either by telephone or in person, following all the safety measures provided by National Organization of Public Health of Greece, by one of the investigators officially participating in the study. A questionnaire will be completed by the examinee, after telephone information about the purpose of the study and after providing a written consent from. In hospitalized patients in the Infectious Diseases Unit, will be informed by the investigators participating in the study and will follow the above procedure. This study was submitted for approval to the research ethic committee and the scientific council of University General Hospital of Ioannina and was accepted.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date June 30, 2021
Est. primary completion date May 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - adult>18 years old - COVID-19 positive patient, via RT-PCR test - Patient referred to the University General Hospital of Ioannina Exclusion Criteria: - Age <18 - Previous nasal surgery, endoscopic sinus surgery - Head and neck radiotherapy - Head injury - Allergic rhinitis - Chronis Rhinosinusitis - Psychiatric/ Neurological disorders - Disorders that altering the level of consciousness (Glasgow Coma Scale <15) - History of smell and taste disorder

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
visual analogue scale
A visual analog scale (VAS) is a measurement device used to quantify a subjective experience.

Locations

Country Name City State
Greece University General Hospital of Ioannina Ioannina Epirus

Sponsors (3)

Lead Sponsor Collaborator
University Hospital, Ioannina 1st DIVISION OF INTERNAL MEDICINE, UNIVERSITY GENERAL HOSPITAL OF IOANNINA, OTORHINOLARYNGOLOGY DEPARTMENT, UNIVERSITY GENERAL HOSPITAL OF IOANNINA

Country where clinical trial is conducted

Greece, 

Outcome

Type Measure Description Time frame Safety issue
Primary oflactory and taste dysfunction in SARS-CoV2 infection 4 WEEKS